A Multicenter Analysis of Factors Associated With Apixaban-Related Bleeding in Hospitalized Patients With End-Stage Renal Disease on Hemodialysis

Annals of Pharmacotherapy

Volumn 51, Issue 11, 2017, Pages 954-960

  Steuber, Taylor D ^a,b   Shiltz, Dane L ^c,d   Cairns, Alex C ^e,f   Ding, Qian ^c   Binger, Katie J ^e,f   Courtney, Julia R ^e,f  

^a AUBURN UNIVERSITY   (United States)

^b HUNTSVILLE HOSPITAL   (United States)

^c FERRIS STATE UNIVERSITY   (United States)

^d SPECTRUM HEALTH   (United States)

^e BUTLER UNIVERSITY   (United States)

^f INDIANA UNIVERSITY HEALTH   (United States)

Author keywords

anticoagulants; anticoagulation; dialysis; end stage renal disease; hematology

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; COHORT ANALYSIS; DRUG EXPOSURE; END STAGE RENAL DISEASE; FEMALE; HEMODIALYSIS; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; LENGTH OF STAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MIDDLE AGED; OUTPATIENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; MULTICENTER STUDY; STATISTICAL MODEL; UNITED STATES;

AGED; COHORT STUDIES; FEMALE; HEMORRHAGE; HUMANS; KIDNEY FAILURE, CHRONIC; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; PYRAZOLES; PYRIDONES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 85031398249     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028017717282     Document Type: Article

References (23)

1. January CT, Wann LS, Alpert JS. 2014 AHA/ACC/HRS guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64:2246-2280.
2. Herzog CA, Asinger RW, Berger AK. Cardiovascular disease in chronic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80:572-586.
3. Kearon C, Akl EA, Ornelas J. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315-352.
4. Boehringer Ingelheim. Pradaxa (dabigatran) [package insert]. Ridgefield, CT: Boehringer Ingelheim; 2010.
5. Janssen Pharmaceuticals. Xarelto (rivaroxaban) [package insert]. Titusville, NJ: Janssen Pharmaceuticals; 2016.
6. Daiichi Sankyo, Inc. Savaysa (edoxaban) [package insert]. Parsippany, NJ: Daiichi Sankyo, Inc; 2015.
7. Bristol-Myers Squibb. Eliquis (apixaban) [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2014.
8. Chan KE, Giugliana RP, Patel MR. Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF. J Am Coll Cardiol. 2016;67:2888-2899.
9. Wang X, Tirucherai G, Marbury TC. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56:628-636.
10. Kufel WD, Zayac AS, Lehmann DF, Miller CD., Clinical application and pharmacodynamic monitoring of apixaban in a patient with end-stage renal disease requiring chronic hemodialysis. Pharmacotherapy. 2016;36:e166-e171. doi:10.1002/phar.1836
11. Deal EN, Pope H, Ross W., Apixaban use among patients with severe renal impairment. Ann Pharmacother. 2014;48:1667. doi:10.1177/1060028014554446
12. Stanton BE, Barasch NS, Tellor KB., Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy. 2017;37:412-419. doi:10/1002/phar.1905
13. Schulman S, Kearon C., Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patient. J Thromb Haemost. 2005;3:692-694.
14. Kaatz S, Ahmad D, Spyropaulos AC, Schulman S., Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015;13:2119-2126.
15. STATA Statistics/Data Analysis. College Station, TX: StataCorp LP; 2013. http://www.stata.com. Accessed June 11, 2017.
16. Elliot MJ, Zimmerman D, Holder RM., Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007;50:433-440.
17. Mavrakanas TA, Samer CF, Nessim SJ, Frisch G, Lipman ML., Apixaban pharmacokinetics at steady state in hemodialysis patients. J Am Soc Nephrol. 2017;28:pii:ASN.2016090980. doi:10.1681/ASN.2016090980
18. Granger CB, Alexander JH, McMurray JJ. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
19. Agnelli G, Buller HR, Cohen A. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799-808.
20. Shah M, Avgil TM, Jackevicius JM. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014;129:1196-1203.
21. Black-Maier E, Piccini JP., Oral anticoagulation in end-stage renal disease and atrial fibrillation: is it time to just say no to drugs? Heart. 2017;103:807-808. doi:10.1136/heartjnl-2016-310540
22. Dager WE, Lee JA., Filtering out use of DOACs in hemodialysis. Ann Pharmacother. 2017;51:511-513. doi:10.1177/1060028016689265
23. Chan NC, Bhagirath V, Eikelboom JW., Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015;11:343-351.